Speaking on Saturday at a World Tuberculosis (TB) Day event, U.N. Secretary-General Ban Ki-moon “called for a global effort to diagnose and treat tuberculosis,” United Press International reports (3/24). According to the WHO, 8.8 million people contracted TB in 2010, and 1.4 million people died of the disease, primarily in low and middle-income countries, CBS News’ “Health Pop” blog notes (Castillo, 3/24). “Let us vow to end the neglect of TB and to end deaths from this disease in our lifetime,” Ban said, adding, “It is critical to support those who lack the means to respond with the care and treatment they need to enjoy healthy and productive lives. … With the right interventions, we can make a major difference,” according to the U.N. News Centre (3/24).
According to a study recently published in a special supplement of the Journal of Infectious Diseases, half of countries receiving grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria provide tuberculosis (TB) services in prisons; “even when TB services were provided to prisoners, they were limited in scope; and “[f]ew of the programs receiving a grant from the Global Fund offered services dedicated to the treatment and prevention of multi-drug resistant TB (MDR-TB),” an aidsmap news story reports. TB is a leading cause of death among incarcerated individuals worldwide, aidsmap notes. The study authors concluded, “There is an urgent need to better understand the financing needs and cost-effective service delivery models for tuberculosis care in prisons,” according to the story (Carter, 3/30).
A joint fact sheet on the U.S.-U.K. Partnership for Global Development is available on the White House website. “Through the Partnership, we are working together to achieve better results by advancing economic growth; preventing conflict in fragile states; improving global health, particularly for girls and women; strengthening mutual accountability, transparency, and measurement of results; and mitigating the effects of climate change,” the fact sheet states, elaborating on joint efforts in each of these areas (3/14).
Largest-Ever Study Of Community-Wide TB Drug Prevention Did Not Improve TB Control In South African Mines
“After seven years of research, the world’s largest study of preventative tuberculosis (TB) therapy has found that untargeted, community-wide distribution of TB prevention drugs did not improve TB control in South African gold mines,” PlusNews reports. “Conducted among 27,000 gold-mine employees in 15 mines, the Thibela TB study tested the theory that treating an entire community with the first-line TB drug isoniazid could result in long-lasting reductions in active TB cases and TB prevalence,” the news service writes (3/9). The study found that “provid[ing] community-wide isoniazid preventive therapy (IPT)” did “not improve TB control,” according to Health-e. “However, evidence showed that there were 63 percent fewer TB cases among individuals in the program during the first nine months of the program, providing reassurance that IPT works for people who take it,” the news service notes (Thom, 3/14).
As part of its series of interviews with CDC staff working on global HIV and tuberculosis (TB) research and development, the Center for Global Health Policy’s “Science Speaks” blog spoke with Jordan Tappero, “who is currently serving as director for the Health Systems Reconstruction Office in the Center for Global Health, an office opened in response to the January 2010 earthquake in Haiti.” In the interview, “Tappero describes his early research in HIV and TB, thoughts on why Uganda is the only sub-Saharan African country not enjoying a reduction in HIV incidence, and how quickly HIV services were restored to people living in Haiti after the January 2010 earthquake,” according to the blog (Mazzotta, 2/29).
“The Kenyan government’s recent failure to adequately treat a patient with extensively drug-resistant tuberculosis (XDR-TB) has some civil society organizations questioning whether the country’s TB program is equipped to diagnose and treat such patients,” PlusNews reports. “The government admits the TB program in Kenya has not been adequately funded despite the country’s big TB burden,” PlusNews writes, adding, “Kenya ranks 13th on the list of 22 high-burden TB countries in the world and has the fifth-highest burden in Africa.”
In this post in USAID’s “IMPACTblog,” guest blogger Joanna Breitstein, director of communications for the TB Alliance, describes an event organized by the Critical Paths to TB Drug Regimens that took place on Monday, “heralding the launch of a new clinical trial that tests tuberculosis drugs in combination.” During the event, “Robert Clay, deputy assistant administrator in USAID’s Global Health Bureau, said that he wants researchers and those who oversee programs in countries to work more closely together,” she writes. A link to video of Clay’s comments is included in the blog (3/20).
“On Tuesday, a global alliance of researchers and scientists — led by the Stop TB Partnership, an umbrella group of health groups — unveiled a ‘blueprint’ to develop a new vaccine [against tuberculosis (TB)] that aims to disrupt transmission in hard-hit countries and communities,” the Wall Street Journal reports. “The blueprint calls for the groups to work together to test new vaccine candidates, and to coordinate fundraising for expansive and expensive human trials, representing the first comprehensive plan of the sort,” the news service writes (Wonacott, 3/20).
“[O]ften seen in the wealthy West as a disease of bygone eras,” Reuters examines rising rates of tuberculosis (TB) — drug-resistant TB in particular — among the world’s rich and poor. “[R]apidly rising rates of drug-resistant TB in some of the wealthiest cities in the world, as well as across Africa and Asia, are again making history,” Reuters writes. According to the news service, “London has been dubbed the ‘tuberculosis capital of Europe,’ and a startling recent study documenting new cases of so-called ‘totally drug-resistant’ TB in India suggests the modern-day tale of this disease could get a lot worse.”
The Center for Global Health Policy’s “Science Speaks” blog interviews tuberculosis (TB) expert Lee Reichman, founding executive director of the New Jersey Medical School Global Tuberculosis Institute, in advance of World TB Day, to be observed on March 24. According to the blog, Reichman discusses “the spread of drug-resistant TB and what he thinks are the most promising advances coming down the scientific pipeline” (Mazzotta, 3/19).